The Hippo signaling pathway in leukemia: function, interaction, and carcinogenesis

Table 1 Expression level of Hippo signaling pathway components in studies of leukemia

Hippo components	Expression level	Cancer type	No patients	Significant value	Samples	P value	References
Lats2	Overexpression	CML	67	Diagnosis marker, good prognosis and improve treatment response	PBMC	< 0.05	[104]
Aurka
Taz
Aurkb
Mst1	No change	AML	52	–	PBMC	> 0.05	[105]
Mst2
Yap1
Mst1	Downregulation	Animal model of lymphoma and leukemia	–	Ability to prevent chromosomal instability	Lymphocytes	< 0.05	[106]
Yap	Overexpression	Leukemia and lymphoma	–	Proliferation	Jurkat cell line	< 0.05	[21]
Lats2	Overexpression	AML	32	Cancer development	PBMC	< 0.05	[86]
Yap	Overexpression	CML	–	Proliferation and leukemogenesis	BMMNCs	< 0.05	[26]
Lats2	Downregulation	ALL	101	Prognostic value	BMMNCs	< 0.05	[87]
Mobkl2a	Downregulation	MCL	77	Pathogenetic role for cancer development	Lymph node	< 0.05	[107]
Mobkl2b
Lats2

AL acute leukemia; ALL acute lymphocytic leukemia; AML acute myeloid leukemia; AURKA/B aurora kinase A/B; BM-Mncs bone marrow mononuclear cells; CLL chronic lymphocytic leukemia; CML chronic myelogenous leukemia; LATS2: large tumor suppressor kinase 2; MST1 macrophage stimulating 1; MCL mantle cell lymphoma; MOBKL2A Mps one binder kinase activator-like 2A; PBMCS peripheral blood mononuclear cells; SMZL splenic marginal zone lymphoma; YAP1 Yes-associated protein 1

ISSN: 1475-2867